Document is current

Article History

Received: 5 April 2023

Accepted: 9 April 2023

First Online: 22 April 2023

Declarations

:

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): <i>Employment or Leadership Position</i>: None; <i>Consultant/Advisory Role</i>: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; <i>Stock Ownership</i>: None; <i>Research Funding</i>: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; <i>Expert Testimony</i>: None; <i>Other Remuneration</i>: None. Renier Brentjens (RB): <i>in the past 2 (two) years he has received the funding listed below from the following sources</i>: Consultancy, Patents & Royalties, Research Funding—BMS; Patents & Royalties—Caribou; Consultancy, Ended employment in the past 24 months—Gracell Biotechnologies, Inc.; Patents & Royalties—Sanofi; Consultant—Atara Biotherapeutics Inc.; Consultant, Scientific Advisory Board member—CoImmune; Consultant, Scientific Advisory Board member—Triumvira. Samir N. Khleif (SNK): <i>Owner/Founder</i>: Georgiamune, LLC; <i>Board Member</i>: Advaxis Board of Directors; <i>Consultant/Advisory Board</i>: aMoon, Adaptive Biotechnology, AstraZeneca, Aummune, Bioline Therapeutics, Coherus, GI Innovation, Incyte, IO Biotechnology, Israel Biotech Fund GP Partners, KAHR Medical, Lycera, McKinsey Health, Merck, Nectin TX, Northwest Biotherapeutics, RAPA Therapeutics, Syndax, Tessa Therapeutics, UbiVac; <i>Research Support</i>: AstraZeneca, BioLine Therapeutics, Bristol-Myers Squibb, HeatBio, IO Biotechnologies, KAHR Medical, Lycera, MediImmune, Merck, Pelican Therapeutics, Syndax; <i>Stock</i>: Advaxis Immunotherapy, Princeton, NJ; Northwest Biotherapeutics, Bethesda, MD; PDS Biotechnology, North Brunswick Township, NJ; IO Biotechnology, Copenhagen; KAHR Medical, Israel; 2022 <i>Speaker Honoraria</i>: AstraZeneca; <i>Memberships:</i> AACR, ASCO, NCPF, NRG, PICI, SITC, TCL—Tomouh Community of Leaders; Editorial Advisory: Omniscient, pte; Springer. Kunle Odunsi (KO): <i>he has received the funding from</i>: AstraZeneca and Tesaro. <i>Scientific Advisory Boards</i>: Daiichi-Sanyo. <i>Co-founder</i>: Tactiva Therapeutics. Katy Rezvani (KR): <i>License agreement and research agreement</i>: Takeda—to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; Affimed. <i>Educational grant</i>: Pharmacyclics; <i>SAB</i>: AvengeBio, Bayer, Caribou Biosciences, GemoAb, GSK, Navan Technologies, and Virogin Biotech. Marco Ruella (MR): <i>he has received the funding listed below from the following sources</i>: Inventor: CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity, and viTToria biotherapeutics; Research Funding: AbClon, Beckman-Coulter, Lumicks, ONI, Orflo; Consultancy/Honoraria: nanoString, GLG, Bayer, Sana, BMS, GSK; Advisory Board: AbClon, viTToria bio, Scailyte; Scientific Founder: viTToria biotherapeutics. Ryan J. Sullivan (RJS): <i>he has received the funding listed below from the following sources:</i> Merck; Novartis; Pfizer; BMS. Bernard A. Fox (BAF): <i>Scientific Advisory Board (Advising/Consulting)</i>: Akoya/PerkinElmer, AstraZeneca/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder/CEO/stock, Ultivue; <i>Research Support</i>: Akoya/PerkinElmer, Bristol-Myers Squibb, Definies/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics/Merck. Igor Puzanov (IP): <i>Consulting/Honoraria</i>: Nektar, Amgen, Roche, Oncorus; <i>Advisory Board</i>: Bristol-Myers Squibb, Regeneron, Nouscom, Nektar; <i>Institutional Clinical Trial Support</i>: Nektar, Idera, Oncosec, Amgen, Immunocore, Dynavax, Rubius, SQZ, ADC; <i>DSMC</i>: Nouscom.